ROLE OF ENDOTHELIN IN THE PATHOGENESIS OF PREECLAMPSIA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The analytical literature review considers the role of endothelin-1 (ET-1) in the development of preeclampsia. The main cause of preeclampsia is impaired placental circulation due to incomplete formation of the vascular system, which leads to placental ischemia and hence increased ET-1 expression. Elevated ET-1 levels induce oxidative and placental reticular stresses that activate a local inflammatory process and the occurrence of endothelial dysfunction that may then be followed by hypertension and proteinuria.

Full Text

Restricted Access

About the authors

L. E MURASHKO

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

L. Z FAIZULLIN

Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

A. V MURASHKO

I.M. Sechenov Moscow State Medical University

Obstetrics and Gynecology Department One, Faculty of Therapeutics

References

  1. Eiland E., Nzerue C., Faulkner M. Preeclampsia 2012. J. Pregnancy. 2012; 2012: 586578.
  2. Burton G.J., Woods A.W., Jauniaux E., Kingdom J.C. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009; 30(6): 473-82.
  3. Khong Y., Brosens I. Defective deep placentation. Best Pract. Res. Clin. Obstet. Gynaecol. 2011; 25(3): 301-11.
  4. Hladunewich M., Karumanchi S.A., Lafayette R. Pathophysiology of the clinical manifestations of preeclampsia. Clin. J. Am. Soc. Nephrol. 2007; 2(3): 543-9.
  5. Rajakumar A., Doty K., Daftary A., Elarger G., Conrad K.P. Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae. Placenta. 2003; 24(2-3): 199-208.
  6. Rajakumar A., Whitelock K.A., Weissfeld L.A., Daftary A.R., Markovic N., Conrad K.P. Selective overexpression of the hypoxia-inducible transcription factor, HIF-2alpha, in placentas from women with preeclampsia. Biol. Reprod. 2001; 64(2): 499-506.
  7. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science. 2005; 308(5728): 1592-4.
  8. Deanfield J., Donald A., Ferri C., Giannattasio C., Halcox J., Halligan S. et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 2005; 23(1): 7-17.
  9. Hui D., Okun N., Murphy K., Kingdom J., Uleryk E., Shah P.S. Combinations of maternal serum markers to predict preeclampsia, small for gestational age, and stillbirth: a systematic review. J. Obstet. Gynaecol. Can. 2012; 34(2): 142-53.
  10. Venkatesha S., Toporsian M., Lam C., Hanai J., Mammoto T., Kim Y.M. et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 2006; 12(6): 642-9.
  11. Powe C.E., Levine R.J., Karumanchi S.A. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011; 123(24): 2856-69.
  12. Levine R.J., Lam C., Qian C., Yu K.F., Maynard S.E., Sachs B.P. et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 2006; 355(10): 992-1005.
  13. Gelinas D.S., Bernatchez P.N., Rollin S., Bazan N.G., Sirois M.G. Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. Br. J. Pharmacol. 2002; 137(7): 1021-30.
  14. Fiore G., Florio P., Micheli L., Nencini C., Rossi M., Cerretani D. et al. Endothelin-1 triggers placental oxidative stress pathways: putative role in preeclampsia. J. Clin. Endocrinol. Metab. 2005; 90(7): 4205-10.
  15. Nelson J., Bagnato A., Battistini B., Nisen P. The endothelin axis: emerging role in cancer. Nat. Rev. Cancer. 2003; 3(2): 110-6.
  16. Struck J., Morgenthaler N.G., Bergmann A. Proteolytic processing pattern of the endothelin-1 precursor in vivo. Peptides. 2005; 26(12): 2482-6.
  17. George E.M., Granger J.P. Endothelin: key mediator of hypertension in preeclampsia. Am. J. Hypertens. 2011; 24(9): 964-9.
  18. McDonald S.D., Malinowski A., Zhou Q., Yusuf S., Devereaux P.J. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am. Heart J. 2008; 156(5): 918-30.
  19. Smith G.C., Pell J.P., Walsh D. Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births. Lancet. 2001; 357(9273): 2002-6.
  20. Vikse B.E., Irgens L.M., Leivestad T., Skjaerven R., Iversen B.M. Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med. 2008; 359(8): 800-9.
  21. McDonald S.D., Han Z., Walsh M.W., Gerstein H.C., Devereaux P.J. Kidney disease after preeclampsia: a systematic review and meta-analysis. Am. J. Kidney Dis. 2010; 55(6): 1026-39.
  22. Bellamy L., Casas J.P., Hingorani A.D., Williams D.J. Preeclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. Br. Med. J. 2007; 335(7627): 974.
  23. Ray J.G., Vermeulen M.J., Schull M.J., Redelmeier D.A. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Lancet. 2005; 366(9499): 1797-803.
  24. Lawlor D.A., Macdonald-Wallis C., Fraser A., Nelson S.M., Hingorani A., Davey Smith G. et al. Cardiovascular biomarkers and vascular function during childhood in the offspring of mothers with hypertensive disorders of pregnancy: findings from the Avon Longitudinal Study of Parents and Children. Eur. Heart J. 2012; 33(3): 335-45.
  25. Stillman I.E., Karumanchi S.A. The glomerular injury of preeclampsia. J. Am. Soc. Nephrol. 2007; 18(8): 2281-4.
  26. Unemori E., Sibai B., Teichman S.L. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia. Ann. N. Y. Acad. Sci. 2009; 1160: 381-4.
  27. Ozler A., Turgut A., Sak M.E., Evsen M.S., Soydinc H.E., Evliyaoglu O., Gul T. Serum levels of neopterin, tumor necrosis factor-alpha and interleukin-6 in preeclampsia: relationship with disease severity. Eur. Rev. Med. Pharmacol. Sci. 2012; 16(12): 1707-12.
  28. Szarka A., Rigo J. Jr., Lazar L., Beko G., Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol. 2010; 11: 59.
  29. Redman C.W, Sacks G.P., Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am. J. Obstet. Gynecol. 1999; 180(2, Pt 1): 499-506.
  30. Sharma A., Satyam A., Sharma J.B. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am. J. Reprod. Immunol. 2007; 58(1): 21-30.
  31. Lynch A.M., Murphy J.R., Gibbs R.S., Levine R.J., Giclas P.C., Salmon J.E., Holers V.M. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. Br. J. Obstet. Gynaecol. 2010; 117(4): 456-62.
  32. Djurovic S., Clausen T., Wergeland R., Brosstad F., Berg K., Henriksen T. Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent preeclampsia. Br. J. Obstet. Gynaecol. 2002; 109(7): 759-64.
  33. LaMarca B.B., Cockrell K., Sullivan E., Bennett W, Granger J.P. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension. 2005; 46(1): 82-6.
  34. Marsden P.A., Brenner B.M. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am. J. Physiol. 1992; 262(4, Pt 1): C854-61.
  35. Xia Y., Kellems R.E. Is preeclampsia an autoimmune disease? Clin. Immunol. 2009; 133(1): 1-12.
  36. Saito S., Shiozaki A., Nakashima A., Sakai M., Sasaki Y. The role of the immune system in preeclampsia. Mol. Aspects Med. 2007; 28(2): 192-209.
  37. Stepan H., Faber R., Wessel N., Wallukat G., Schultheiss H.P., Walther T. Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. J. Clin. Endocrinol. Metab. 2006; 91(6): 2424-7.
  38. Veillon E.W.Jr., Keiser S.D., Parrish M.R., Bennett W., Cockrell K., Ray L.F. et al. 17-Hydroxyprogesterone blunts the hypertensive response associated with reductions in uterine perfusion pressure in pregnant rats. Am. J. Obstet. Gynecol. 2009; 201(3): 324; e1-6.
  39. Raijmakers M.T., Dechend R., Poston L. Oxidative stress and preeclampsia: rationale for antioxidant clinical trials. Hypertension. 2004; 44: 374-80.
  40. Yung H.W., Calabrese S., Hynx D., Hemmings B.A., Cetin I., Charnock-Jones D.S., Burton G.J. Evidence of placental translation inhibition and endoplasmic reticulum stress in the etiology of human intrauterine growth restriction. Am. J. Pathol. 2008; 173(2): 451-62.
  41. Zhang K., Kaufman R.J. From endoplasmic-reticulum stress to the inflammatory response. Nature. 2008; 454(7203): 455-62.
  42. Jain A., Olovsson M., Burton G.J., Yung H.W. Endothelin-1 induces endoplasmic reticulum stress by activating the PLC-IP(3) pathway: implications for placental pathophysiology in preeclampsia. Am. J. Pathol. 2012; 180(6): 2309-20.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies